Mumbai, July 23 -- Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto(R), a biosimilar to the reference product Enbrel(R) (Etanercept), in Australia. Nepexto(R) will be promoted by Generic Health, its local partner and a leading provider of high-quality generic prescription, injectable and over-the counter medicines, to expand access to patients in Australia.
Published by HT Digital Content Services with permission from Capital Market....